Stay updated with breaking news from Dose Level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Precigen, Inc. presented pipeline and corporate updates at the 41st Annual J.P. Morgan Healthcare Conference. PRGN-2012 AdenoVerse™ Immunotherapy in RRP. Overview: PRGN-2012 is an investigational... | January 12, 2023
– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – – PRGN-3006...
– Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase complete...
Precigen, Inc. (NASDAQ:NASDAQ:PGEN) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Steven Harasym - Vice President and Head of Investor Relations Helen...
– Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; Mayo...